This site is updated Hourly Every Day

Trending Featured Popular Today, Right Now

Colorado's Only Reliable Source for Daily News @ Marijuana, Psychedelics & more...

Post: So mushroom for growth: Bioxyne subsidiary inks psilocybin deal with Swiss pharma company

Picture of Anschutz Medical Campus

Anschutz Medical Campus is an independent website not associated or affiliated with CU Anschutz Medical Campus, CU, or Fitzsimons innovation campus.


Recent Posts

Anschutz Medical Campus

So mushroom for growth: Bioxyne subsidiary inks psilocybin deal with Swiss pharma company

BLS and Cy Biopharma AG have entered a commercial supply and collaboration deal. Picture: Getty Images. Sponsored content

Bioxyne says BLS Wholesalers has inked a commercial supply and collaboration agreement with Cy Biopharma AG of Switzerland to develop psilocybin products targeting treatment of depression and pain in Australia and New Zealand.

Bioxyne ( ASX:BXN ) says the deal with the biopharmaceutical company will also provide BLS with the opportunity to manufacture and supply the Australian, New Zealand, US, and European clinical trials market with novel psilocybin products.

BLS will also be able develop proprietary formulations and drug delivery methods, and supply Australian patients via the authorised prescriber scheme.

BLS Wholesalers is a wholly owned Breathe Life Sciences (BLS) subsidiary, which in turn is a wholly-owned subsidiary of BXN. It is the company’s licencing entity operating in Australia.

BXN says Cy Biopharma will exclusively supply BLS with Psilocybe cubensis fungi for Australia and New Zealand.

BLS Wholesalers Pty Ltd is the only licensed Australian manufacturer of MDMA and psilocybin.

BXN announced in April the company had been granted an upgraded and amended wholesale licence for MDMA and psilocybin (schedule 8) finished products by the Therapeutic Goods Administration (TGA). Focused on psychedelic development

Founded in 2020 and based in Switzerland since 2021, Cy Biopharma AG is a privately held, international biopharma company targeting treatments for rare conditions.Led by CEO Dr Anton Hoos, the company is focused on development of psychedelics, 5-HT2A receptor agonists which can lead to profound changes in perception, cognition, and mood.Cy Biopharma is planning clinical development for psilocybin and engineering next generation 5HTx agonism-based novel psychedelic molecules with the goal of delivering improved pharmacological profiles suited to its target indications.In the US, Cy Biopharma Inc has been supporting an FDA-approved pilot trial in oncological pain via a philanthropic partnership.Initiated by principal investigator Dr Beaussant at the Harvard Dana-Farber Cancer Centre, the study seeks to examine the potential of psilocybin to treat opioid-resistant pain.In South America, Cy Biopharma is engaged in process research and manufacture to ensure professional cultivation of naturally derived serotonin receptor agonists.The company has been granted multiple import permits for psychedelics […]

Leave a Reply

Your email address will not be published. Required fields are marked *

You Might Be Interested...